ISIN | LU2041628244 |
---|---|
Valor Number | 49478504 |
Bloomberg Global ID | |
Fund Name | JSS Sustainable Equity - Future Health E CHF acc |
Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
Fund Provider | J. Safra Sarasin Investmentfonds AG |
Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). The assets of the fund are mainly invested worldwide either directly (min. 67% of the SubFund’s assets) or indirectly in equity securities that offer an exposure to one or multiple emerging and transformational health trends. The Sub-Fund invests in leading companies and niche players whose products and services contribute to the improvement of health outcome and the dampening of rising healthcare costs. |
Peculiarities |
Current Price * | 87.77 CHF | 03.07.2025 |
---|---|---|
Previous Price * | 87.43 CHF | 02.07.2025 |
52 Week High * | 107.80 CHF | 16.07.2024 |
52 Week Low * | 84.60 CHF | 11.04.2025 |
NAV * | 87.77 CHF | 03.07.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 140,989,821 | |
Unit/Share Assets *** | 16,102,614 | |
Trading Information SIX |
YTD Performance | -10.24% |
31.12.2024 - 03.07.2025
31.12.2024 03.07.2025 |
---|---|---|
1 month | -1.81% |
03.06.2025 - 03.07.2025
03.06.2025 03.07.2025 |
3 months | -5.90% |
03.04.2025 - 03.07.2025
03.04.2025 03.07.2025 |
6 months | -11.51% |
03.01.2025 - 03.07.2025
03.01.2025 03.07.2025 |
1 year | -15.75% |
03.07.2024 - 03.07.2025
03.07.2024 03.07.2025 |
2 years | -14.07% |
03.07.2023 - 03.07.2025
03.07.2023 03.07.2025 |
3 years | -20.52% |
05.07.2022 - 03.07.2025
05.07.2022 03.07.2025 |
5 years | -19.44% |
06.07.2020 - 03.07.2025
06.07.2020 03.07.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 8.85% | |
---|---|---|
Sanofi SA | 6.04% | |
AstraZeneca PLC | 5.42% | |
UnitedHealth Group Inc | 5.03% | |
Johnson & Johnson | 5.03% | |
Danaher Corp | 5.00% | |
Gilead Sciences Inc | 4.59% | |
Novo Nordisk AS Class B | 4.54% | |
argenx SE | 4.50% | |
Intuitive Surgical Inc | 4.02% | |
Last data update | 31.05.2025 |
TER | 1.58% |
---|---|
TER date | 31.10.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.80% |
Ongoing Charges *** | 1.57% |
SRRI ***
|
|
SRRI date *** | 30.06.2025 |